Clinical Trial Update: OX40, Venetoclax, Avelumab, Glasdegib, Gemtuzumab Ozogamicin, and Azacitidine in Relapsed or Refractory Acute Myeloid Leukemia [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial evaluating combinations including OX40, venetoclax, avelumab, glasdegib, gemtuzumab ozogamicin, and azacitidine in relapsed or refracto…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• AZACITIDINE (AZACITIDINE)
• Avelumab (avelumab)
• Gemtuzumab ozogamicin (gemtuzumab ozogamicin)
• Glasdegib (glasdegib)
• OX40 (OX40-targeted agent)
• Venetoclax (venetoclax)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2023-05-24